Phaseline

Companies › Tetra Discovery Partners

Tetra Discovery Partners: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Other; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Zatolmilast (BPN14770)
Phosphodiesterase 4D inhibitor
PDE4DPhase 3Fragile X SyndromeSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05367960Zatolmilast (BPN14770)Phase 3Fragile X SyndromeOtherSep 2027

Targets

PDE4D (1)

Companies with the same targets

Amgen MediciNova Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA Shionogi Ganzhou Hemay Pharmaceutical Merck & Co. (MSD) Arcutis Biotherapeutics Integrative Skin Science and Research

Companies built like this

Mezzion Pharma Huons Biopharma Neuren Pharmaceuticals Prove pharm Neuraptive Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.